Business Description
Impact BioMedical Inc
NAICS : 541714
SIC : 2833
ISIN : US45259L2051
Total Employee Number:
8Description
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 2.13 | |||||
Debt-to-EBITDA | -57.35 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.77 | |||||
Beneish M-Score | -0.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37 | |||||
3-Year EBITDA Growth Rate | 10.2 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | 35.1 | |||||
3-Year Book Growth Rate | -63.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.21 | |||||
9-Day RSI | 49.27 | |||||
14-Day RSI | 46.17 | |||||
3-1 Month Momentum % | -20.42 | |||||
6-1 Month Momentum % | 3.9 | |||||
12-1 Month Momentum % | -15.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.16 | |||||
Quick Ratio | 0.13 | |||||
Days Inventory | 199.54 | |||||
Days Sales Outstanding | 83.43 | |||||
Days Payable | 399.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -108.8 | |||||
Shareholder Yield % | -22.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -1111.43 | |||||
Operating Margin % | -14562.86 | |||||
Net Margin % | 2254.29 | |||||
EBITDA Margin % | -1140 | |||||
FCF Margin % | -1451.43 | |||||
OCF Margin % | -1451.43 | |||||
ROE % | 31.09 | |||||
ROA % | 4.46 | |||||
3-Year ROIIC % | 0.94 | |||||
ROC (Joel Greenblatt) % | -10758.14 | |||||
ROCE % | -21.04 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 13.75 | |||||
PS Ratio | 440 | |||||
PB Ratio | 4.4 | |||||
EV-to-EBIT | -47.74 | |||||
EV-to-EBITDA | -184.5 | |||||
EV-to-Revenue | 2103.31 | |||||
EV-to-FCF | -144.91 | |||||
Earnings Yield (Greenblatt) % | -2.09 | |||||
FCF Yield % | -1.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:IBO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Impact BioMedical Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.035 | ||
| EPS (TTM) ($) | -0.1 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 61.96 | ||
| 14-Day RSI | 46.17 | ||
| 14-Day ATR ($) | 0.028724 | ||
| 20-Day SMA ($) | 0.436925 | ||
| 12-1 Month Momentum % | -15.68 | ||
| 52-Week Range ($) | 0.37 - 0.83 | ||
| Shares Outstanding (Mil) | 107.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Impact BioMedical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Impact BioMedical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 84 days | ||
| General meeting for 2026 | 2026-11-05 10:00 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | 0.45 (+4.84%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.63 (-0.27%) | ||
| Annual report for 2025 | 2026-03-11 | 0.61 (+6.85%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 0.53 (+2.65%) | ||
| General meeting for 2025 | 2025-11-05 10:00 | 0.53 (+4.47%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.55 (+3.70%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.55 (+4.51%) | ||
| Annual report for 2024 | 2025-03-28 | 2.28 (-8.80%) |
Show
Entries
Impact BioMedical Inc Frequently Asked Questions
What is Impact BioMedical Inc(IBO)'s stock price today?
The current price of IBO is $0.44. The 52 week high of IBO is $0.83 and 52 week low is $0.37.
When is next earnings date of Impact BioMedical Inc(IBO)?
The next earnings date of Impact BioMedical Inc(IBO) is 2026-11-06 Est..
Does Impact BioMedical Inc(IBO) pay dividends? If so, how much?
Impact BioMedical Inc(IBO) does not pay dividend.
Guru Commentaries on AMEX:IBO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Impact BioMedical Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers